Biotechnology is the use of biology in the production of new products, services, and organisms with the aim of improving human health and society. In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of that figure. Not surprising when you think that healthcare focused biotech companies are battling to solve some of our biggest health concerns; turning an ageing society into a longevity society by supporting longer and healthier lives. In this episode of The Next Five, Paul Little, CEO of Vesper Bio discusses frontotemporal dementia and the impact of it on human health and society, the biotech solutions being sort to combat the disease as well as what he describes as a Malthusian crisis around biotech funding. Dr Ann Beliën, Founder and CEO of Rejuvenate Biomed addresses the problems of Sarcopenia as well as the biotech solutions for it and how Biotech companies use creative ways to secure funding. Gianmario Verona, President of Human Technopole, highlights the importance of industry collaboration and how innovation centres can help propel the biotech sector forward. 

Sources: FT Resources, WHO, JP Morgan, Alzheimersresearchuk, IQVIA 

This content is paid for by Yes Milano and is produced in partnership with the Financial Times' Commercial Department.

Hosted on Acast. See acast.com/privacy for more information.